Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial

• Published in: Journal of sexual medicine Vol. 2; no. 5; p. 685
• Main Authors: Carrier, Serge, Brock, Gerald B, Pommerville, Peter J, Shin, Janey, Anglin, Greg, Whitaker, Steven, Beasley, Jr, Charles M
• Format: Journal Article
• Language: English
• Published: Netherlands 01.09.2005
• Subjects: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Adult; Aged; Canada; Carbolines - administration & dosage; Carbolines - adverse effects; Carbolines - therapeutic use; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction - drug therapy; Erectile Dysfunction - etiology; Erectile Dysfunction - physiopathology; Humans; Male; Middle Aged; Phosphoric Diester Hydrolases - metabolism; Severity of Illness Index; Tadalafil; Treatment Outcome; Vasodilator Agents - administration & dosage; Vasodilator Agents - adverse effects; Vasodilator Agents - therapeutic use; Canada

Erectile dysfunction (ED) is a highly prevalent, often undertreated condition. This 12-week, double-blind, parallel, placebo-controlled study was conducted at 25 sites in Canada to evaluate the efficacy and safety of oral tadalafil, a phosphodiesterase type 5 inhibitor, for the treatment of ED. Men...